Efficacy and Safety in Phase 3 EVOLVEMS-1 After Switching from Prior MS Therapies or Continuing on Diroximel FumarateS. Wray,F. Then Bergh, A. Wundes,D. Arnold,J. Drulovic, E. Jasinska,J. Bowen, D. Negroski, R. Naismith,S. Hunter, M. Gudesblatt,H. Chen,S. Levin, S. Shankar,M. Barnett,S. Kapadia,J. Mendoza,B. SingerEUROPEAN JOURNAL OF NEUROLOGY(2022)引用 0|浏览5暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要